Related Experiment Videos
[Chemotherapy for osteosarcoma--trends in recent years]
S Fujinami1, K Nakaseko, Y Ogihara
1Dept. of Orthopaedic Surgery, Mie University School of Medicine.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 1, 1993
Summary
Osteosarcoma treatment has evolved significantly. Modern chemotherapy regimens, including high-dose methotrexate (HD-MTX), cisplatin (CDDP), and ifosfamide (IFO), show superior outcomes compared to older methods.
Area of Science:
- Oncology
- Orthopedic Surgery
- Pharmacology
Context:
- Osteosarcoma treatment has evolved significantly over the past 20 years.
- Review of 49 osteosarcoma cases treated since 1970.
- Analysis of chemotherapy efficacy, outcomes, and adverse effects.
Purpose:
- To evaluate the changing landscape of osteosarcoma chemotherapy.
- To compare treatment outcomes across different therapeutic eras.
- To identify areas for improvement in current osteosarcoma treatment protocols.
Summary:
- Cases were categorized into four groups based on treatment era and chemotherapy agents: pre-1977 (no systematic therapy), 1977-1982 (high-dose methotrexate [HD-MTX] alone), 1977-1982 (preoperative HD-MTX with postsurgical cisplatin [CDDP]), and post-1988 (preoperative MTX with CDDP, and ifosfamide [IFO] or novel agents as needed).
- Patients receiving treatment after 1988 demonstrated superior results compared to earlier cohorts.
- Despite advancements, current therapies for osteosarcoma still present challenges, necessitating ongoing research.
Impact:
- Highlights the improved efficacy of modern chemotherapy combinations in osteosarcoma.
- Underscores the importance of systematic and multimodal treatment approaches.
- Provides a basis for future research into novel therapeutic strategies for osteosarcoma.